<DOC>
	<DOCNO>NCT02094235</DOCNO>
	<brief_summary>This multicenter , double-blind , vehicle-control study 0.05 % 0.2 % E6005 ointment . Pediatric subject atopic dermatitis ( AD ) group two ; elder group ( childhood - adolescent : 7 15 year age ) young group ( child : 2 6 year age ) accord sequential cohort confirm safety .</brief_summary>
	<brief_title>A Phase 1/2 Study E6005 Pediatric Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Inclusion Criteria 1 . Pediatric outpatient diagnose AD age 2 15 year time write informed consent . Diagnosis AD make accordance `` Guidelines Management Atopic Dermatitis '' Japanese Dermatological Association . 2 . Mild moderate clinical symptom appear baseline area application study drug possible , except skin face/head nondermal area mucosa 3 . Evaluable skin lesion appear baseline . `` Evaluable skin lesion '' mean rash area 25 100 cm2 trunk extremity , least one dermal symptom ( erythema , exudate/eschar , excoriation lichenification ) must moderate severity . 4 . Continuous use appropriate moisturizer least 14 day baseline 5 . Females childbearing potential must negative pregnancy test baseline able practice effective contraception study period include followup period 6 . Virile male females childbearing potential , whose partner consent practice contraception throughout study period receive explanation use informed consent form separatelyprepared assent form 7 . Patients whose legally acceptable representative ( caregiver ) able consent write participate study able adhere protocol requirement . For patient age 12 year old time inform consent , write consent obtain patient well legally acceptable representative ( caregiver ) . Also patient age 12 year , write informed consent obtain whenever possible . Exclusion Criteria 1 . Use biological product may affect pathological evaluation AD within 6 month start study treatment 2 . Concurrent recent use certain topical systemic medication phototherapy without sufficient washout period , except hydrocortisone butyrate preparation use area unsuitable application study drug discretion investigator 3 . Currently Kaposi 's varicelliform eruption , scabies , molluscum contagiosum , impetigo contagious , psoriasis , connective tissue disorder , Netherton 's syndrome , etc , may affect pathological evaluation AD 4 . Any past history present illness serious allergy anaphylactic shock , anaphylactic reaction anaphylactoid reaction , past history present illness drug allergic reaction hypersensitivity 5 . Has active infection require oral intravenous administration antibiotic , antifungal antivirus agent baseline 6 . Currently advanced disease highly abnormal laboratory test result may affect safety subject implementation study 7 . Difficulty venous access blood collection 8 . Any past history present illness malignant tumor , lymphoma , leukemia lymphoproliferative disorder , except nonmelanoma skin carcinoma ( e.g. , squamous cell carcinoma basal cell carcinoma ) completely remove recur metastasize least 5 year 9 . Scheduled surgery study 10 . Concurrently enrol another clinical study use investigational drug device within 30 day date inform consent 11 . Ineligible participate study reason , judgment investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Dermatitis</keyword>
	<keyword>Atopic</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Child</keyword>
</DOC>